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SUMMARY
The generation of humanized ectopic ossicles (hOss) in mice has been proposed as an advanced trans-
lational and fundamental model to study the human hematopoietic system. The approach relies on the
presence of human bone marrow-derived mesenchymal stromal cells (hMSCs) supporting the engraft-
ment of transplanted human hematopoietic stem and progenitor cells (HSPCs). However, the func-
tional distribution of hMSCs within the humanized microenvironment remains to be investigated.
Here, we combined genetic tools and quantitative confocal microscopy to engineer and subsequently
analyze hMSCs0 fate and distribution in hOss. Implanted hMSCs reconstituted a humanized environ-
ment including osteocytes, osteoblasts, adipocytes, and stromal cells associated with vessels. By im-
aging full hOss, we identified rare physical interactions between hMSCs and human CD45+/CD34+/
CD90+ cells, supporting a functional contact-triggered regulatory role of hMSCs. Our study highlights
the importance of compiling quantitative information from humanized organs, to decode the interac-
tions between the hematopoietic and the stromal compartments.
INTRODUCTION
The lifelong production of all human blood cell lineages is ensured by hematopoietic stem cells (HSCs)
(Me´ndez-Ferrer et al., 2010; Morrison and Scadden, 2014). In adults, HSCs0 functions are maintained and
tightly regulated in the specialized bone marrow (BM) microenvironment, referred to as the BM niche
(Me´ndez-Ferrer et al., 2010; Morrison and Scadden, 2014). This environment is defined by unique physical
properties (Engler et al., 2006; Guilak et al., 2009; Keung et al., 2010) and includes differentiated cells,
extracellular matrix, and signaling factors (Rieger et al., 2009; Zhang and Lodish, 2008) essential for
cell differentiation, survival (Knapp et al., 2016), and self-renewal (Kunisaki and Frenette, 2012; Me´n-
dez-Ferrer et al., 2010). However, the precise cellular and molecular composition of the human hemato-
poietic niche remains elusive (Bourgine et al., 2018; van Pel et al., 2015). Our understanding of human
hematopoiesis largely relies on the analogy made with the mouse system (Schepers et al., 2015). In re-
ality, despite commonly inherited genetic traits, HSC basic biology differs across species and the corre-
sponding interactions with their niches are not fully conserved (Doulatov et al., 2012; van Pel et al., 2015).
In consequence, information derived from murine studies does not systematically correlate with the hu-
man system, raising concerns about their direct relevance toward therapeutic developments (Doulatov
et al., 2012).
Advanced xenotransplantation models offer robust engraftment and development of human hematopoi-
esis in mouse bones (Rongvaux et al., 2014). This has significantly contributed to the progressive under-
standing of human HSC functions in healthy and pathological setups (Antonelli et al., 2016; Reinisch
et al., 2016). However, such humanized mouse models are incompatible with the organizational and func-
tional study of the HSC niche, because the BM microenvironment remains entirely murine.
As an alternative, the possibility to engineer ectopic humanized ossicles (hOss) using human BM-derived
mesenchymal stromal cells (hMSCs) is receiving increasing attention (Bourgine et al., 2014; Reinisch et al.,
2016; Scotti et al., 2013), with demonstration of robust human blood engraftment in both healthy and ma-
lignant scenarios (Abarrategi et al., 2017; Martine et al., 2017; Reinisch et al., 2016). Although this is attrib-
uted to the presence of hMSCs, their contribution in the functional organization of the niche remains to be
investigated.
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Here, we propose the genetic engineering of hMSCs together with the use of a recently developed deep
multicolor imaging confocal analysis (Coutu et al., 2017) to achieve a first quantitative assessment of the
distribution and role of hMSCs in hOss. We previously reported a developmental approach to bone organ
formation, by in vitro chondrogenic priming of hMSCs (Bourgine et al., 2014; Scotti et al., 2013). Following
hypertrophic cartilage (hyC) formation, the generated tissues remodel into hOss upon subcutaneous im-
plantation in humanized mice (Fritsch et al., 2018) by recapitulating the endochondral ossification process
(Kronenberg and Kronenberg, 2003). We target the further exploitation of this approach to engineer and
characterize customized hematopoietic bone organs, here exemplified by the generation of niches over-
expressing stromal-derived factor 1 alpha (SDF1a), through compositional and distributional assessment
of their human cellular compartments.
The validation of the methodology bears relevance toward deciphering the human hematopoietic and
skeletal systems using advanced and modular or tunable models of higher translational relevance.
RESULTS
Primary hMSCs Can Be Genetically Engineered without Altering Their Capacity to Form
Hypertrophic Cartilage
Before cartilage formation, hMSCs were transduced (Figure 1A) using a VENUS (mock control) or VENUS-
SDF1a lentivirus (Figure S1). The transduction allowed the generation of homogeneous VENUS and
VENUS-SDF1a hMSCs populations (>93% and 96% using VENUS and VENUS-SDF1a viruses, respectively,
Figure 1B). The VENUS-SDF1a transduction led to a significant SDF1a overexpression (31-fold increase in
RNA levels when compared with VENUS hMSCs, Figure 1C), with transduced and untransduced MSCs dis-
playing unchanged phenotypes (Figure S2).
Cells were subsequently seededon collagenmeshes andprimed to formhyC.Over the 5-week course of in vitro
culture, the total numberof cells in thehyC remainedstable (1.33106 and1.23106 atweeks1and5 respectively,
Figure S3). During this period, the monitoring of proteins in hyC supernatant revealed comparable release pro-
files of angiogenic (vascular endothelial growth factor), osteoinductive (bone morphogenetic protein-2), bone
remodeling (matrix metalloproteinase-13), and inflammatory (interleukin-8) factors, suggesting similar develop-
ment of the templates by untransduced (primary hyC) or transduced hMSCs (VENUS and VENUS-SDF1a hyC)
(Figure 1D). VENUS-SDF1a hyC secreted significantly higher amounts of SDF1a (4-fold increase at day 3, Fig-
ure 1D), although a progressive decrease was observed over time.
At the end of the in vitro culture, histological analysis indicated the successful formation of mature hyC in all
groups, characterized by the large presence of glycosaminoglycans (safranin O, Figure 1E) and a mineral-
ized ring at the periphery of the tissue (alizarin red, Figure 1E). Differentiation was confirmed by RT-PCR,
revealing activation of chondrogenic (Collagen 2, Sox 9, Figure 1F) and hypertrophic genes (RUNX2,
ALP, BSP, OSX, Figure 1F) in all hyCs. Importantly, VENUS-SDF1a hyCs were shown to maintain a marked
SDF1a overexpression (Figure 1F) when compared with primary and VENUS hyCs.
Hypertrophic Cartilage with a Targeted SDF1a Enrichment Can Be Generated
After demonstrating the similar quality of hyCs and hOss derived from primary or VENUS hMSCs (Figure S4),
VENUS hyCs were further used as the control group allowing for the tracing of hMSCs via the VENUS signal.
Multicolor confocal analysis of thick hyC sections was performed to investigate the presence and distribu-
tion of cells and SDF1a in the templates. VENUS cells were homogenously distributed within the tissue,
largely embedded into a collagen type 2-rich matrix with detectable SDF1a proteins (Figure 2A). High-res-
olution imaging revealed presence of the chemokine intracellularly in both VENUS and VENUS-SDF1a cells
in their corresponding hyC (Figure 2B). The SDF1a protein was also found associated with the extracellular
matrix (ECM), as shown by colocalization with collagen type 2, in a more abundant fashion in VENUS-SDF1a
samples (Figure 2B). To confirm microscopic observations, hyCs were lysed and assessed for their content
in a panel of growth factors, including SDF1a. VENUS and VENUS-SDF1a hyCs displayed comparable pro-
tein contents (Figure 2C) except a 2-fold SDF1a enrichment in the VENUS-SDF1a templates (Figure 2C).
Consistent with previous observations (Dalonneau et al., 2014; Pelletier et al., 2000), the reported decrease
in secreted SDF1a over culture time (Figure 1D) can be explained by SDF1a0s capacity to bind to the ECM,
leading to its progressive embedding. We thus report the successful tuning of cartilage tissue0s composi-
tion, through a targeted enrichment of SDF1a content.
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Molecularly Engineered hyC Can Remodel into Humanized Bone Organs of Distinct Blood
Compositions
In vitro-engineered VENUS and VENUS-SDF1a hyCs were subcutaneously implanted in mice (Figure 3A).
After 6 weeks, when hyCs are expected to be remodeled into bone tissue, animals were intravenously trans-
planted with CD34+ cord-blood-derived hematopoietic cells to reconstitute human hematopoiesis (Fig-
ure 3A). After a total in vivo period of 12 weeks, VENUS and VENUS-SDF1a hyCs remodeled into ectopic
ossicles exhibiting macroscopic evidence of vascularization (Figure 3B). Microtomography scans (Fig-
ure 3C) revealed the formation of mature bone tissue with no quality differences between the two hOss
types, consisting in a spheroid organ of 18G 2.1 mm3 (Figure S5). Confocal microscopy allowed to identify
Figure 1. Primary hMSCs Can Be Genetically Engineered without Altering Their Capacity to Form Hypertrophic Cartilage
(A) Experimental design for generation of hypertrophic cartilage (hyC). SDF1a, stromal-derived factor 1 alpha.
(B) Primary hMSCs were successfully transduced with the VENUS and VENUS-SDF1a lentiviruses, as assessed by flow cytometry. nR 4 biological replicates.
(C) The VENUS-SDF1a transduction led to a significantly higher expression of SDF1a levels in corresponding cells before hyC formation. **p < 0.01, using
non-parametric Mann-Whitney t test. nR 5 biological replicates.
(D) All hyC display similar protein secretion patterns during in vitro culture time, but VENUS-SDF1a hyC releases higher amounts of SDF1a. nR 3 biological
replicates. BMP-2, bone morphogenetic protein-2; MMP-13, matrix metalloproteinase-13; VEGF, vascular endothelial growth factor; IL-8, interleukin-8.
(E) VENUS and VENUS-SDF1a successfully displayed features of mature hypertrophic cartilage tissue following 5 weeks of in vitro culture, as assessed by
histological analysis. Safranin O staining reveals the presence of glycosaminoglycans (red), whereas alizarin red reveals the presence of mineralized tissue
(red). Scale bars, 500 mm.
(F) After 5 weeks of in vitro culture, VENUS-SDF1a hyC successfully displayed a typical hypertrophic molecular profile while exhibiting a significant SDF1a
increase.
**p < 0.01, using one-way ANOVA. nR 4 biological replicates. Col2, collagen type 2; RunX2, Runt-related transcription factor 2; ALP, alkaline phosphatase;
BSP, bone sialoprotein; OSX, osterix. Data are represented as mean G SEM.
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human blood cells in the hOss, forming heterogeneous ‘‘islets’’ of human hematopoiesis, indicating suc-
cessful engraftment (Figure 3D).
Human blood populations were quantified by flow cytometry in retrieved hOss and corresponding
mouse bones (Figures S6A and S6B). Engraftment of human blood cells was similar with an average
hCD45 chimerism level of 40% (Figure 3E). VENUS hOss and mouse bones displayed comparable fre-
quencies of naive and more committed blood populations (Figures 3E and S6C), whereas hOss overex-
pressing SDF1a showed significantly higher frequencies of multipotent progenitors (MPPs) and common
myeloid progenitors (CMPs)/megakaryocyte-erythroid progenitor (MEPs) (2.7- and 2.4-fold increase,
respectively) and superior HSPC and HSC content (1.8- and 1.9-fold increase, respectively), although
not reaching significance.
The functionality of hCD45/CD34+ cells retrieved from mouse bones or hOss was evaluated by in vitro col-
ony formation unit (CFU) assays. Cells were capable of efficiently giving rise to all myeloid colonies, but the
hCD45/CD34+ fraction derived from hOss displayed a significantly higher potential to form hematopoietic
colonies, including GEmM, than the corresponding population retrieved from mouse bones (Figure S6D).
No differences in CFU activity were observed between cells retrieved from VENUS or VENUS-SDF1a hOss,
suggesting that the SDF1a overexpression did not affect stem and progenitor functionalities. We thus vali-
date the generation of SDF1a-customized hOss, composed of an increased frequency of HSPCs without
alterations of their functionality.
Figure 2. Hypertrophic Cartilage with a Targeted SDF1a Enrichment Can Be Generated
(A) VENUS and VENUS-SDF1a hyC consist in cartilage pellets (macroscopic view, left) in which hMSCs (VENUS positive)
and the SDF1a protein are found abundantly in the collagen-rich matrix, as assessed by immunofluorescence analysis of
thick hyC sections. Col2, collagen type 2. Scale bars, 500 mm.
(B) SDF1a is more abundant in the ECM of VENUS-SDF1a hyC, as revealed by high-resolution immunofluorescent
imaging. Scale bars, 20 mm. Col2, collagen type 2.
(C) A significant and specific SDF1a enrichment is obtained in the VENUS-SDF1a hyC, as assessed by protein
quantification. n = 3 biological repeats. **p < 0.01, using one-way ANOVA test. Data are represented as
mean G SEM.
iScience 19, 504–513, September 27, 2019 507
Quantitative Microscopy of Bone Organs Reveals the Reconstitution of a Human
Mesenchymal Niche including Rare Mesenchymal-Hematopoietic Physical Interactions
Deepconfocal analysis onboth types of hOss offered aquantitative understandingof the reconstitutedBMenvi-
ronment. Serial sectioning of hOss allowed gathering comprehensive 3D information (Figures 4A and S7A) and
indicated an intense vascularization surrounding the hOsswith its cavity largely filled by BMcells. The hOss were
also connected to the host nervous system as shown by evidences of innervation (peripherin, Figure S7B).
The presence of hMSCs in both VENUS and VENUS-SDF1a organs was identified by VENUS expression
(Figure S8A). The segmentation of VENUS cells (Figure S8A) in corresponding sections (Figure S8B) allowed
determining the average number of hMSCs per hOss. From the 1.2 3 106 hMSCs present in the hyC at the
time of implantation, only 0.1 3 106 were still populating the hOss, corresponding to a 90% decrease (Fig-
ure S8C). To corroborate this finding, flow cytometry quantification of VENUS cells after hOss digestion was
also performed, giving a number of hMSCs per hOss of 0.063 106 (Figure S8C). The difference is likely due
to difficulty to retrieve bone-embedded hMSCs and adipocytes. The observed hMSC death was not due to
the animal irradiation, because non-irradiated hOss gave similar numbers (0.07 3 106, Figure S8C).
Remarkably, in the engineered hOss, hMSCs were associated with an important fate diversity following the re-
modeling of hyC. HMSCs0 fates in bone organs were quantified by specific segmentation strategies (c.f.
Methods section and Figures S8 and S9). First, no significant differences could be observed between VENUS
and VENUS-SDF1a hOss, indicating that the hMSCs0 genetic modification did not impact their subsequent
fate decisions upon hOss formation. The capacity to manipulate hMSCs without impairing their endochondral
program allows the stringent assessment of SDF1a effects. As such, the previously observed distinct human
blood composition in VENUS-SDF1a hOss can be strictly attributed to the factor overexpression.
In all hOss, hMSCs were abundantly found within the BM stroma (stromal, 45% and 47% in VENUS and
VENUS-SDF1a hOss respectively, Figure 4B), exhibiting a fibroblast-like shape and positivity for CD90 (Fig-
ure S9A). A large fraction of them (47% and 50%, respectively; Figure 4B) was directly associated with vascu-
lature (0–1 mm distance to vessels). The hMSCs0 enrichment at vessel sites was confirmed by comparison to
Figure 3. Molecularly Engineered hyC Can Remodel into Humanized BoneOrgans of Distinct Blood Compositions
(A) Experimental design for the generation of humanized ossicles (hOss). Engineered hyCs are implanted into
immunocompromised animals. Mice are humanized 6 weeks later by intravenous transplantation of human CD34+
isolated from cord blood. Constructs are retrieved 6 weeks later for analysis.
(B and C) (B) VENUS and VENUS-SDF1a hyCs successfully remodeled into ossicles, as shown macroscopically by blood
colonization and (C) by microtomographic scans revealing the formation of mature bone tissue. Ossicles were retrieved
after 12 weeks in vivo. Scale bars, 0.5 mm.
(D) Humanized ossicles display a chimeric blood composition organized in ‘‘islets’’ of human hematopoieisis.
(E) SDF1a-overexpressing ossicles displayed higher frequencies of human blood populations, as assessed by
flow cytometry. nR 18 biological replicates from four independent experiments. *p < 0.5, using one-way ANOVA
test. CMPs, common myeloid progenitors; HSCs, hematopoietic stem cells; HSPCs, hematopoietic stem and progenitor
cells; MEPs, megakaryocyte-erythroid progenitors; MPPs, multipotent progenitors. Data are represented as
mean G SEM.
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a random dots distribution (Figure S9C). HMSCs also differentiated into the osteogenic lineage in the form
of osteocytes embedded in the bone matrix (osteocytes, Figures 4B and S9A), accounting for 36% (VENUS
hOss) and 41% (VENUS-SDF1a hOss) of total VENUS cells. Lining osteoblasts were less abundant (19% in
VENUS hOss versus 12% in VENUS-SDF1a hOss, Figures 4B and S9A). To a lower extent, we also identified
hMSCs differentiated into the adipogenic lineage, as shown by the presence of VENUS-positive adipocytes
(Figure S7D).
To obtain a better understanding of the observed in vivo fate diversity, we further investigated the propor-
tion of hMSCs committed to certain lineages before implantation, at the hyC stage (5 weeks in vitro cul-
ture). The Sox-9 and RUNX2 transcription factors are typically associated with chondrogenic (Akiyama
et al., 2002) and osteoblastic (Ducy et al., 1997) differentiation, respectively; 41.3% (G5.6) of the cells
Figure 4. Quantitative Microscopy of Bone Organs Reveals the Reconstitution of a Human Mesenchymal Niche
Including Rare Mesenchymal-Hematopoietic Physical Interactions
(A) Multidimensional confocal immunofluorescence imaging allows for the reconstitution of hOss for 3D quantitative
information retrieval (left). Top view of a transverse hOss section (right) illustrating the internal bone marrow cavity (DAPI)
and intense peripheral vascularization (lamimin). Scale bars, 400 mm.
(B) Top: implanted hMSCs (VENUS positive) demonstrate fate plasticity by acquiringmultiple niche cell phenotypes. Scale
bars, 20 mm. Bottom: fate quantification of VENUS hMSCs based on the segmentation of immunofluorescence data.
Stromal cells, venus+/CD90+/stroma localization; osteocytes, venus+/ALP-/localization in bone nodules; osteoblasts,
venus+/ALP+/localization at the bone and bone marrow interface; vascular associated, venus+/distance to lamimin+
vessels < 1 mm; ALP, alkaline phosphatase. nR 3 biological replicates.
(C) The SDF1a protein was expressed by blood cells and also found more abundantly in VENUS cells from the VENUS-
SDF1a ossicles. Right and b are magnification panels.
(D) Deep confocal analysis of hOss allows for the identification and localization of a rare HSPC subset (arrow, hCD45/
CD34/CD90), found directly in contact with hMSC-derived niche cells. n = 10 events detected in 5.9 mm3 of tissue
scanned. Data are represented as mean G SEM.
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were positive for Sry-box 9 (Sox-9), 6.3% (G5) expressed the Runt-related transcription factor 2 (RUNX2),
and 10.8% (G5.6) were both RUNX2 and Sox-9 positive (Figure S10). No cells showed positivity for the adi-
pocytic marker peroxisome proliferator-activated receptor gamma (Lefterova et al., 2014). As such, the ma-
jority of our cells were chondrocytes (Sox-9 positivity), hypertrophic chondrocytes (Sox-9 and/or RUNX2
positivity), or osteoblasts (RUNX2 positivity). Interestingly, despite the 5-week course of differentiation,
29.9% G 1.6% maintained the expression of Stro-1, a progenitor marker associated with multipotency
(Lin et al., 2011). This indicates that some hMSCs are not fully committed at the end of the in vitro differen-
tiation stage and acquire their definitive function after implantation.
Further immunofluorescenceanalysisof theossicleswasperformed.SDF1a staining revealed thepresenceof the
protein in the marrow (Figure 4C), expressed by blood cells (Dar et al., 2006). The SDF1a protein could also be
detected in hMSCs-derived cells from VENUS-SDF1a hOss (Figure 4C). Acquisition of deepmulticolor staining
was furtherperformed for the identificationofhMSC-derivednichecells (positive forVENUS)andparticularHSPC
populations within engineered hOss. This allowed the localization of a very rare subset of HSPCs (hCD45+/
CD34+/CD90+) described to be enriched for functional HSCs, which was consistently in physical contact (less
than 1 mm distance) with VENUS cells, in both VENUS and VENUS-SDF1a niches (n = 10 events detected in
5.9mm3of tissuescanned,Figure4D). Toensure that those interactionsdidnot result froma randomdistribution,
we investigated the probability for HSPCs touching an hMSC (Figure S11). This probability was found to be 36%
(G11), although 100% of the HSPCs we found were in contact with hMSCs.
This recurrent physical interaction between the human stromal and naive hematopoietic compartments,
combined with the finding that SDF1a customization leads to changes in frequencies of hematopoietic
populations, supports a functional contact-triggered regulation of HSPCs by the human mesenchymal
compartment, to date only reported in mouse studies (Gomariz et al., 2018; Rongvaux et al., 2011).
DISCUSSION
We report the engineering and characterization of customized human hematopoietic bone organs. The
method relies on the genetic modification of primary hMSCs, their priming to recapitulate the develop-
mental program of endochondral ossification (Kronenberg and Kronenberg, 2003), and quantitative multi-
dimensional imaging of the reconstituted human BM environment.
The study of hematopoiesis in a humanized context is a primary challenge. The generationof transgenic animals
supporting human engraftment is associated with some limitations (Devoy et al., 2012), including time-
consuming single-gene targeting, the unpredictable biological outcome (e.g., embryonic lethality, low effi-
ciency, absence of recognizable phenotypes), and the often non-tissue-specific nature if at all conditional.
Instead, our strategy relies on the exploitation and characterization of the hOss model, using hMSCs as cellular
vectors for the targeted delivery of factors influencing the composition of the human blood compartment. The
introduced modification is thus confined within the BM tissue as ensured by hMSC-derived niche cells.
The biological validation of themethod was performed using SDF1a as a known factor influencing stem cell
behavior. SDF1a has been reported both as stem cell chemoattractant (Aiuti et al., 1997; Lapidot and Kol-
let, 2002; Mohle et al., 1998) and pro-quiescent molecule (Itkin and Lapidot, 2011; Tzeng et al., 2011), thus
offering multiple readouts to validate the effects of its overexpression in hOss. Pre-existing molecular en-
gineering approach (Carretta et al., 2017; Chen et al., 2012) models did not investigate the effect of the
genetic modification on the reconstituted human niche environment. As a direct consequence, impact
on the blood compartment could not be strictly attributed to the factor0s secretion. Here, the SDF1a over-
expression was shown to specifically affect the human blood composition while not affecting the fate and
distribution of implanted hMSCs. The capacity to manipulate hMSCs without impairing their endochondral
program is a pre-requisite for the direct assessment of SDF1a effects. We observed a specific enrichment in
CMPs/MEPs, MPPs, and HSC populations in SDF1a-overexpressing hOss. All these populations express
the CXCR4 receptor (Toni et al., 2011), thus being sensitive to the SDF1a chemoattractant effect (Peled
et al., 1999). The previously reported SDF1a-driven mobilization of CD34+ cells by stromal cells included
the recruitment of more committed erythroid, lymphoid, and myeloid lineages (Bleul et al., 2002). Our ob-
servations are thus in line with the existing literature, although our study is the first exploiting a humanized
approach to evidence an SDF1a-triggered effect. Although our model was previously validated for the
engraftment of fully functional HSCs (Fritsch et al., 2018), secondary transplantation would be required
to assess putative SDF1a effects on the self-renewal of long-term repopulating stem cells.
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Interestingly, the association of SDF1a with proteoglycans—the main constituents of cartilaginous ECM
(Roughley and Lee, 1994)—was reported to strongly promote the migration of HSPCs (Netelenbos et al.,
2002). This might suggest that the observed effects result from preferential homing at the time of engraft-
ment (Lapidot and Kollet, 2002), although a different cycling rate of HSPCs cannot be excluded.
In our study, we used advancedmicroscopy tools to monitor hMSCs within the engineered tissues, from the
in vitro hyC stage to the fully remodeled hOss. As easily accessible organs tunable in size, quantitative 3D
information on the hOss cellular composition could be retrieved and offered a comprehensive understand-
ing of the human niche in this in vivo setting. This revealed a remarkable degree of hMSCs0 plasticity in the
model, giving rise to several niche phenotypes, including lining osteoblasts, osteocytes, stromal cells, and
adipocytes. Distance analyses indicated not only a strong association of hMSCs with vasculature but also
direct physical interactions with HSPCs. The observed fate diversity may derive from a pool of hMSCs with
no signs of chondrogenic or osteoblastic commitment at the hyC stage. However, lineage-committed
hMSCs have also been described as capable of transdifferentiation (Song and Tuan, 2004).
Although previous studies reported the presence of hMSCs in ossicles (Abarrategi et al., 2017; Martine
et al., 2017; Reinisch et al., 2016), their functional status has not been rigorously demonstrated beyond their
support for human blood engraftment. Our work evidences for the first time a functional regulatory role of
hMSCs in the model, validated by the SDF1a customization leading to distinct changes in frequencies of
hematopoietic populations. These were achieved despite the relatively low number of hMSCs composing
the niche and supporting human blood cell engraftment. Collectively, these findings reinforce the notion
that hMSCs are essential niche players (Me´ndez-Ferrer et al., 2010; Morrison and Scadden, 2014) in the en-
gineered ossicles and support a contact-triggered regulation of HSPCs by themesenchymal compartment,
only previously reported in mouse studies (Rongvaux et al., 2011). The detection of a high number of inter-
actions of a more specific HSC phenotype (CD45+/CD34+/CD38-/CD45RA-/CD90+/CD49f+) (Fares et al.,
2014), which requires challenging immunofluorescence multiplexing, would, however, be required to pro-
vide direct evidence of a physical interaction between hMSCs and functional HSCs.
The functional role of hMSCs in the hOss model supports their use for the molecular engineering of human
niches. The importance of the proximity between hMSCs and HSPCs could be further evaluated by over-
expression of signaling molecules requiring direct contact of adjacent cells for influencing their fate deci-
sions, e.g., Notch ligands (Artavanis-Tsakonas et al., 1999). The paradigm of customization can also be
further explored with additional factors putatively affecting stem cell homing/localization/function in path-
ological scenarios (e.g., by engraftment of leukemic primary material) and include the impact assessment
on the human niche compartment. In fact, the hOss could be valuable for the identification of specific hu-
man niche cell populations, derived from the implanted hMSCs. This is of particular importance in patho-
logic scenarios, in which the role of the stroma and associated factors in disease evolution remains elusive
(Schepers et al., 2015, 2013). Our model could thus help deciphering the complex phenotypes and func-
tions associated with hMSCs (Mo et al., 2016; Nombela-Arrieta et al., 2011) in myeloid or lymphoid malig-
nancies. Along the same line, our model could also be exploited to study the engraftment of metastatic
solid tumors (e.g., breast, prostate) that naturally migrate to bones, including those for which SDF1a has
been shown to be highly expressed in BM sites of tumor metastasis (Roccaro et al., 2014).
Toward these objectives, the exploitation of dedicated cell lines may not only facilitatemolecular engineer-
ing of hMSCs but also potentially lead to their higher survival in the BM. This would maximize the therapeu-
tic delivery of factors impacting engrafted healthy or malignant blood populations. However, so far no
hMSC line was proved capable of recapitulating the endochondral process.
Finally, using similar knockout or knockin strategies in hMSCs, we also envision the possibility of identifying
key molecular players of the endochondral program, by studying their impact on hMSC fate decision. The
ossicle would thus be exploited as a developmental model of human bone formation.
Limitations of the Study
For immunofluorescence analysis, the hCD45+/CD34+/CD90 + phenotype was used to identify HSPCs. Of
this population, 24.6% are CD34+/CD38-/CD45RA-CD90+, of which 5% were reported to be functional
HSCs in freshly isolated cord blood (Notta et al., 2011). The hCD45+/CD34+/CD90 + population thus con-
tains ca. 1.2% functional HSCs. Detection of functional HSCs will require improved HSC markers. In
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addition, owing to the large required effort, only a small number of these cells were imaged in ossicles. A
higher number will allow robust statistical analysis of human MSC-HSPC interactions.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.08.006.
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Transparent Methods section 
Isolation and culture of hMSCs 
All experiments were conformed to the regulatory standards of the ETH Zurich, the University 
Hospital of Basel and the University of Zürich.  hMSCs were isolated from human BM aspirates 
from the iliac crest, after ethical approval (EKBB, Ref. 78/07) and informed donor consent 
from patients. Bone marrow aspirates (20 mL volume) were harvested from healthy donors 
(N≥3, females and males 30 to 65 years old) using a biopsy needle inserted through the 
cortical bone, and immediately transferred into plastic tubes containing 15,000 IU heparin. 
After diluting the marrow aspirates with phosphate buffered saline (PBS) at a ratio of 1:4, 
nucleated cells were isolated using a density gradient solution (Histopaque, Sigma Chemical, 
Buchs, CH).  Complete medium consisting in α-minimum essential Medium (αMEM) with 10% 
fetal bovine serum, 1% HEPES (1 M), 1% sodium pyruvate (100 mM) and 1% of Penicillin–
Streptomycin– Glutamine (100X) solution (all from Gibco). Nucleated cells were plated at a 
density of 33×106 cells/cm3 in complete medium supplemented with 5 ng/ml of fibroblast 
growth factor-2 (FGF-2, R&D Systems) and cultured in a humidified 37 °C/5% CO2 incubator. 
Medium was changed twice in a week. HMSCs were selected on the basis of adhesion and 
proliferation on the plastic substrate one week after seeding. In this study, donors were pre-
selected based on their capacity to differentiate in vitro into the chondrogenic lineage. 
 
Plasmid constructs 
The lentivector VENUS-SDF1 was obtained by cloning the SDF1α gene extracted from the 
pBABE puro SDF-1 alpha plasmid (Addgene, plasmid #12270) was cloned by restriction digest 
into a third generation lentiviral backbone (Schambach et al., 2006) containing the VENUS 
transgene. The VENUS lentivector consisted in the same system without the SDF1α gene. 
 
Virus production and hMSC transductions 
Third generation vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentivirus was 
produced in human embryonic kidney (HEK) 293T cells and titrated using NIH-3T3 fibroblasts. 
The generation of VENUS and VENUS-SDF1α hMSC was performed by plating cells at 6000 
cells/cm2 in 60-mm dishes the day preceding the transduction. HMSC were transduced by 
overnight incubation with the corresponding lentivirus at a MOI of 20, expanded for up to 
four passages and purified by flow cytometry based on their positive expression for the 
VENUS transgene. 
 
Hypertrophic cartilage engineering 
Two million hMSCs were seeded onto type I collagen meshes (cylinder of 6 mm in diameter, 
2 mm thick; Ultrafoam, Davol) corresponding to a density of 3.5 × 103 cells/mm3 to generate 
hyC. Tissues were cultured for 3 weeks in chondrogenic medium (DMEM supplemented with 
penicillin-streptomycin glutamine (Invitrogen), HEPES (Invitrogen), sodium pyruvate 
(Invitrogen), ITS (Insulin, Transferrin, Selenium) (Invitrogen), Human Serum Albumin 0.12% 
(CSL Behring), 0.1mM ascorbic acid (Sigma), 10−7M dexamethasone (Sigma) and 10ng/ml TGF-
β3 (Novartis)), followed by 2 weeks in a serum-free hypertrophic medium (supplemented 
with 50 nM thyroxine, 7 mM β-glycerophosphate, 10 nM dexamethasone, 0.25 mM ascorbic 
acid and 50 pg/mL IL-1β ) (Scotti et al., 2013).  
 
Gene expression analysis 
Total RNA was extracted from cells using TRIzol (Invitrogen, Carlsbad, CA), treated with DNAse 
and retrotranscribed into cDNA, as previously described (Frank et al., 2002). Real-time RT-PCR 
was performed with the ABIPrism 77000 Sequence Detection System (Perkin Elmer/Applied 
Biosystem, Rotkreuz, Switzerland) and expression levels of genes of interest were normalized 
to GAPDH. Primers and probe sets of osteogenic genes (Collagen type 2, Sox-9, RUNX2, 
Alkaline phosphatase, Osterix, Bone sialoprotein type 1, SDF1α) were designed and used as 
previously described (Frank et al., 2002). 
 
Biochemical Stainings 
After in vitro culture, constructs were fixed in 4% (vol/vol) paraformaldehyde; if necessary, 
decalcified with 7% (vol/vol) EDTA solution (Sigma); and embedded in paraffin. Sections (5 
μm thick) were stained with H&E (Baker) or Alizarin red solution. Histological sections were 
analyzed using an Olympus BX-61 microscope. 
 
Protein quantification 
Protein levels were determined in supernatants collected during in vitro chondrogenic 
differentiation of hyC, and in the final hyC tissue retrieved after 5 weeks of in vitro culture. 
Samples were analyzed for their content of a panel of growth factors, chemokines, and 
metalloproteinases, according to the manufacturer’s instructions (R&D Immunoassay Kit) and 
by a Luminex device. Supernatant values were expressed as amounts produced per day per 
single hyC (pg/mL/day/construct). ECM values correspond to the total content per construct 
(pg/construct). 
 
Human ossicles generation 
In vitro engineered hyC were implanted in subcutaneous pouches of hMCSF / hTPO / hSIRP / 
-/-Rag2 -/-IL2rg mice, with a maximum of 4 implants per animal. Six weeks after ossicle 
implantation, 6-8x105 cord blood-derived CD34+ cells were pooled from a minimum of 5 
donors  and injected intravenously into sublethally irradiated immuno-compromised mice 
(400cGy) as previously reported (Rongvaux et al., 2014, 2011; Scotti et al., 2013). Humanized 
ossicles were retrieved 6 weeks post-transplantation for subsequent analysis. A minimum of 
4 technical experimental replicates was performed. The human cord blood biopsies were 
approved by the Cantonal ethics committee of Zurich and obtained after informed donor 
consent. 
 
Mice 
Animals consisted in female RAG2−/−γc−/− mice humanized by insertion of human TPO, 
human M-CSF and human SIRPα. Human TPO and human M-CSF were inserted by knock-in 
replacement, performed using  Velocigene Technology as reported previously (Rongvaux et 
al., 2011; Willinger et al., 2011). In addition, the Human SIRPα expression was achieved by 
transgenesis using a BAC in the same genetic background, as previously described (Strowig et 
al., 2011). All mice were maintained at the University Hospital Zurich animal facility according 
to the guidelines of the Swiss Federal Veterinary Office, and all the experiments were 
approved by the Veterinäramt of Kanton Zurich, Zurich, Switzerland (animal permit 
187/2013).  
 
Flow cytometry 
In vitro samples; cells were retrieved from engineered hyC following digestion using a 
previously established protocol (Sittinger et al., 2012). Prior to intracellular and nuclear 
staining, cells were first fixed with fresh formaldehyde 4% and permeabilized by adding ice-
cold 100% methanol slowly to pre-chilled cells, while gently vortexing, to a final concentration 
of 90% methanol. Cells were then stained for the detection of Sox9 (Abcam), PPARg 
(Lifesciences), RunX2 (Cell Signaling) and Stro-1 (Biolegend) markers. Analysis were 
performed on a LSR Fortessa (BD Biosciences). 
In vivo samples; Mice were euthanized with CO2 asphyxation and ossicles as well as mouse 
femur and fibia were removed.  Explanted human ossicles and mouse bones were crushed 
using a mortar and pestle, digested at 37°C for 45 min in DMEM (Invitrogen), 10% FCS 
(Invitrogen), 10mM HEPES (Invitrogen), 0.4% collagenase II (Worthington) and 0.02% DNase I 
(Worthington) and washed with PBS containing 2% human Serum and then filtered on a 70 
μm cell strainer. The resultant cells were blocked for nonspecific-antibody binding (human 
and mouse FcR Blocking Reagent, Miltenyi Biotec) and subsequently stained for the markers 
of interest. All samples were analyzed on a FACS Aria III (BD Biosciences) or LSR Fortessa (BD 
Biosciences). Antibodies used are listed in Table S1.  
 
Colony-forming-unit assay (CFU)  
For the colony-forming-unit assays, 1000 hCD45+hlin-hCD34+ cells from ossicle and femur 
bone marrow were sorted and plated in methylcellulose medium (StemCell Technologies) 
containing hIL-3 100 ng/ml, hIL-6 50 ng/ml, hIL-11 50 ng/ml, hSCF 50 ng/ml, hTPO 250 ng/ml, 
hEPO 20 U/ml, hGM-CSF 250 ng/ml and hFlt3L 50 ng/ml. Cultures were maintained at 37°C in 
5% CO2 and scored after 12-14 days.  
 
Micro-computerized tomographic analysis 
Microtomography was performed with in vivo retrieved ossicles. After fixation in formalin and 
storage in PBS, microcomputerized tomography data were acquired using a Phoenix nanotom 
m scanner (General Electric) with 0.5 mm aluminum filtered X-rays (applied voltage, 70 kV; 
current, 260 μA). Transmission images were acquired during a 360° scan rotation with an 
incremental rotation step size of 0.25°. Reconstruction was made using a modified Feldkamp 
algorithm at an isotropic voxel size of 2.5 μm. Threshold-based segmentation and 3D 
measurement analyses (bone mineral density and volume) were performed using the ImageJ 
software (ImageJ; National Institutes of Health) with the BoneJ (Meijer et al., 2007) and 3D 
Shape (Phinney et al., 1999) extensions. 3D rendering of the structures was performed using 
VGStudio MAX 2.2 software (Volume Graphics). 
 Immunofluorescence stainings 
In vitro or in vivo samples were fixed in 4% (vol/vol) paraformaldehyde; if necessary, 
decalcified with 7% (vol/vol) EDTA solution (Sigma). Embedding was performed using 4% low-
melting agarose (Sigma) and 150 to 250µm thick sections were cut using a Leica VT1200S 
vibratome with Endurium® low-profile ceramic injector blades (Cadence Inc.). For 
immunostainings, all steps were performed at room temperature with gentle rocking. 
Sections were blocked and permeabilized with TBS (final concentration 0.1M Tris, 0.15M 
NaCl, pH: 7.5) containing 0.05% Tween-20, 20% DMSO (both from Sigma) and 10% donkey 
serum (Jackson ImmunoResearch). This buffer was also used to dilute all primary antibodies, 
secondary detection reagents and blocking reagents. After blocking/permeabilization, 
endogenous avidins and biotins were block using the kit from Vector Labs, each step one hour 
followed by 30 minutes washes. Sections were then sequentially stained with primary, highly 
cross-absorbed secondary antibodies and streptavidins (when required), each overnight with 
5x1h washes in between using TBS containing 0.05% Tween-20. For staining with two or more 
primary antibodies raised in the same species, sequential staining was performed with the 
following blocking steps between: 0.12-0.25mg/mL IgG of the same species as the antibody 
that needs blocking, 0.12-0.25mg/mL monovalent Fab fragments raised in donkey against the 
IgG species used in the previous step (both reagents from Jackson ImmunoResearch, both 
steps overnight), followed if required by additional avidin/biotin blocking steps. A list of 
primary and secondary antibodies is provided as Table S2 and Table S3 respectively. 
 
Optical clearing and mounting of sections 
Sections were optically cleared with graded series of 2,2’-thiodiethanol (TDE, Sigma) diluted 
in TBS until 100% TDE was reached. The final mounting solution consisted of 100% TDE with 
0.1M N-propyl gallate (pH: 8.5, Sigma). The refractive index of this solution was measured 
using a handheld refractometer (Atago) and adjusted to 1.518 with TDE or TBS. Sections were 
mounted using custom-made silicone spacers (Grace Biolabs) on custom-made size 00, 
D263M borosilicate coverglass (RI: 1.518, Menzel-Gläser). Sections were mounted on size 1.5 
coverslips.  
 
Confocal microscopy 
Confocal microscopy was performed on a Leica TCS SP5 equipped with three photomultiplier 
tubes, two HyD detectors, five lasers (405nm blue diode, argon [458, 476, 488, 496 and 
514nm], and three helium neon [543, 594 and 633nm]) using type F immersion liquid (RI: 
1.518) and a 20X multiple immersion lens (NA 0.75, FWD 0.680mm). All scans were acquired 
at 20-25oC, 400Hz, in the bidirectional mode, with z-spacing of 2.49mm (the optical slice 
thickness of the optics used was 2.69mm). Images were acquired either with a 1.1x to 2.2x 
optical zoom at a resolution of 512x512 or 1024x1024.  
 
Statistics 
Data are presented as means ± standard error of the mean and were analyzed using the 
GraphPad Prism software. Single comparison was performed using the non-parametric Mann 
Whitney t-test assuming a non-gaussian distribution of the values. Multiple comparisons were 
performed using the one-way ANOVA assuming a non-gaussian distribution of the values. 
Statistical significant differences were defined as: * =p < 0.05, ** = p < 0.01, *** = p <0 .001. 
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Supplementary Materials 
Antibody Conjugated 
fluorophore 
Specie Company Product 
number 
human lineage 
cocktail 
PE Cy5 Mouse Invitrogen 348807 
human CD45 eFluor 450 Mouse eBioscience 48-0459-42 
human CD90 PE Mouse BD 555596 
Human 
CD38-biotin 
Streptatividin- 
Pacific orange 
Mouse Biolegend 303518 
human CD34 PECy7 Mouse BD 348811 
human CD45RA APC eFluor 780 Mouse eBioscience 47-0458-42 
mouse CD45 APC Mouse Biolegend 109814 
 
Table 1. List of antibodies used for flow cytometry analysis, Related to Figure 3. 
 
 Primary antibody Specie Company Product number 
Collagen type 2 Mouse Abbiotec 250484 
SDF1α Rabbit eBiosciences 14-7992-81 
Laminin Rabbit Novus BIologicals NB300-144 
Peripherin Rabbit Biolegend/Covance PRB-576C 
Alkaline 
Phosphatase 
Goat R&D systems AF2910 
CD34 Rabbit Novus Biologicals NBP2-38322 
CD90 Sheep R&D systems AF2067 
human CD45 Rat AbD Serotec MCA345GT 
GFP Chicken Aveslab GFP-1020 
 
Table 2. List of primary antibodies used for confocal immunofluorescence analysis, Related  
to Figure 4. 
 
 
Secondary 
antibody 
Specie Company Product number 
Anti-rat 
Alexa Fluor 488 
Donkey Thermofischer A-21208  
Anti-rabbit 
Alexa Fluor 555 
Donkey Thermofischer A-31572  
Anti-mouse 
Alexa Fluor 555 
Donkey Thermofischer A-31570  
Anti-rat Donkey Thermofischer A-21096 
Alexa Fluor 680 
Anti-rat CF633 Donkey Biotium 20137 
Anti-goat 
Alexa fluor 594 
Donkey Thermofischer A-11058  
Anti-rabbit CF633 Donkey Biotium 20125 
Anti-chicken Donkey Jackson  
Immunoresearch 
703-545-155 
 
Table 3. List of secondary antibodies used for confocal immunofluorescence analysis,  
Related to Figure 4. 
 
 
 
 
Figure S1. Lentivectors overview used for the generation of VENUS and VENUS-SDF1α 
hMSCs populations, Related to Figure 1. 
 
 
  
Figure S2. Comparable phenotypes of hMSCs untransduced (WT = primary hMSCs) and 
transduced with the VENUS or VENUS-SDF1α lentiviruses. All cells express CD73, CD90, 
CD29, CD44, CD146 but not CD34 and CD45. Data compiled from flow cytometry analysis, 
Related to Figure 1. 
 
 
 
 Figure S3. Quantification by DNA content of hMSC number in hyC over in vitro culture time, 
Related to Figure 1. n=3 biological replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure S4. Histological and microcomputed analysis of engineered tissues, Related to Figure 
3. (A) Representative MicroCT reconstitution of hyC and hOss generated from untransduced 
(primary hMSCs) or transduced hMSCs (VENUS & VENUS-SDF1α). (B) Quantification of the 
A 
B 
C 
mineral volume in the respective hyC and hOss. Data were then normalized to the average 
volume of the respective tissues, to display the final mineralized volume over total volume. 
n≥3. (C) Histological analysis of hOss generated from primary or transduced hMSCs (VENUS 
and VENUS-SDF1α). No differences could be observed between the two groups. hOss were 
explanted 12 weeks post-in vivo implantation. Scale bar = 500µm. 
 
 
Figure S5. Mean volume of hOss (18 ±2.1 mm3) calculated by microtomography, Related to 
Figure 3. n=6 biological replicates. Data are represented as mean +/- SEM. 
 
 
 
 
 
 
 Figure S6. Bone marrow analysis of mouse bones and human ossicles, Related to Figure 3. (A) 
Gating strategy for analysis of HSPCs populations engrafted in mouse bones or humanized 
ossicles. (B) Phenotypic markers defining HSPCs, HSCs, MPPs, Myeloid progenitors (MylPs), 
CMPs/MEPs and Granulocyte-monocyte progenitors (GMPs) populations. (C) Flow cytometry-
derived frequencies of GMP amd MyLP populations in engineered hOss and mouse bones  at 
the end of the 12 weeks in vivo period. n ≥12. (D) Human CD45+/CD34+ cells maintained in 
VENUS and VENUS-SDF1α ossicles displayed a superior capacity to form myeloid colonies in 
vitro. CFU: colony forming unit. GEmM: Colony-forming unit-Granulocyte, Erythroid, 
macrophage, Megakaryocyte. GM: Colony-forming unit-granulocyte and macrophage. E: 
colony forming unit-erythroid. G: colony forming unit granulocyte. M: colony forming unit 
macrophage. n ≥12 biological replicates. *p<0.05, **p<0.01. Data are represented as mean 
+/- SEM. 
 
 
Figure S7. Confocal analysis of VENUS-SDF1α ossicles, Related to Figure 4. (A) 
Multidimensional confocal immunofluorescence imaging of VENUS-SDF1αhOss for 3D 
quantitative information retrieval (left). Top view of a transversal hOss section (right) 
illustrating the internal bone marrow cavity (DAPI) and intense peripheric vascularization 
(lamimin). Scale bar = 400µm. (B) Humanized ossicles display evidences of innervation 
(arrows), proving connection to the host nervous system. Dashline indicates the external 
border of the hOss. Scale bar = 100µm. (C) Implanted hMSC (VENUS positive) are detected in 
association with the established vasculature, which includes both arterioles (left) and 
sinusoids (right). Scale bar = 20µm. (D) Implanted hMSCs (VENUS positive) differentiate into 
adipocytes, as assessed by the presence of cytosolic lipid droplets autofluorescent in the blue 
channel (DAPI). Scale bar = 20µm.  
  
 
 
Figure S8. Imaging strategy for hMSCs quantification in humanized ossicles, Related to Figure 
4. (A) Generation of isosurfaces for hMSC-VENUS fate determination/quantification using the 
Imaris software. (B) Generation of isosurfaces of whole sections based on the combination of 
all channels using the Imaris software. This is used to derive the volume of section scanned 
and normalized the number of objects per volume of section. (C) Quantification of VENUS 
expressing hMSCs by segmentation of confocal scans and by flow cytometry based on the 
VENUS signal following digestion of hOss. One point represents one ossicle, the bar 
represents the mean. Significance was assessed by one-way ANOVA test. 
 
 
 
 
 
 
 
 
 Figure S9. Isosurface strategies for the quantification of hMSCs fate in humanized ossicles, 
Related to Figure 4. (A) Rationale and representative example leading to the generation of 
isosurfaces for hMSC-VENUS fate determination/quantification. ALP: alkalyne phosphatase. 
(B) Generation of vasculature isosurfaces using laminin expression as a proxy for vasculature. 
(C) Distance transform between VENUS objects and Laminin, and comparison with random 
dots distribution. Data are represented as mean +/- SEM. 
 
Figure S10. Intracellular staining of hMSCs retrieved from engineered hyC (5 weeks of in vitro 
differentiation), Related to Figure 4. Stainings for the transcription factors Sry-box 9 (Sox-9), 
Runt-related transcription factor 2 (RunX2), peroxisome proliferator-activated receptor 
gamma (PPARg) and Stro-1 were used as chondrocytic, osteoblastic, adipocytic or progenitor 
marker, respectively. Most of the hMSCs display lineage commitment, but some maintain the 
expression of the Stro-1 progenitor marker. n=2 independent experiments, N≥6 biological 
replicates. Data are represented as mean +/- SEM. 
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 Figure S11. Probability assessment of voxels to randomly distribute in a HSPCs touching a 
hMSCs, Related to Figure 4. (A) Confocal images of detected HSPCs (red objects defined by 
hCD45+/CD34+/CD90+) touching hMSCs (VENUS). (B) Maximal diameter calculation of HSPCs 
(n=10) allowed to determine the HSPCs radius (5µm). Any blood cells in physical contact with 
a hMSC will thus have its center maximum 5µm away from this hMSC. (C) Distance probability 
between randomly distributed voxels and hMSCs within the human bone marrow volume. 
DAPI VENUS HSPCs 
This was calculated by distance transform using the segmented isosurface of hMSCs (VENUS 
signal) and of the human hematopoietic compartment (based on the human CD45 signal). The 
central line (thick pattern) represent the mean. The upper and lower lines represent the mean 
of maximal and minimal values respectively. All voxels falling within a 0 to 5µm distance 
(corresponding to the maximum HSPCs radius) would thus necessary be confined in a blood 
cells touching a hMSC. Thus, the probability that a voxel falls directly within a blood cell in 
physical contact with hMSCs is of 36%. Data were compiled out of n=4 confocal scans.  
 
